MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

2021 ◽  
Vol 21 ◽  
pp. S355-S356
Author(s):  
Claudia Lebedinsky ◽  
Sujan Kabir ◽  
Steven Warner ◽  
Golam Mohi ◽  
Huyuan Yang ◽  
...  
Keyword(s):  
High Risk ◽  
Phase I ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Secondary Myelofibrosis

A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2561-2561 ◽  
Author(s):  
Sonja Loges ◽  
Bjorn Torre Gjertsen ◽  
Michael Heuser ◽  
I Ben-Batalla ◽  
David Micklem ◽  
...  
Keyword(s):  
High Risk ◽  
Phase I ◽  
Phase I Study ◽  
Kinase Inhibitor

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

2021 ◽  
Author(s):  
Katrina S. Pedersen ◽  
Patrick M. Grierson ◽  
Joel Picus ◽  
A. Craig Lockhart ◽  
Bruce J. Roth ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor

scholarly journals Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (22) ◽  
pp. 36750-36760 ◽  
Author(s):  
Tongtong Zhang ◽  
Qing Li ◽  
Shanshan Chen ◽  
Yang Luo ◽  
Ying Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Breast

scholarly journals Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

2014 ◽  
Vol 56 (2) ◽  
pp. 395-400 ◽  
Author(s):  
Gail J. Roboz ◽  
H. Jean Khoury ◽  
Elias Jabbour ◽  
Wilena Session ◽  
Ellen K. Ritchie ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Leukemia ◽  
Myelodysplastic Syndrome ◽  
Phase I ◽  
Phase I Trial ◽  
Kinase Inhibitor

scholarly journals Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

2011 ◽  
Vol 18 (4) ◽  
pp. 1092-1100 ◽  
Author(s):  
Adil I. Daud ◽  
Smitha S. Krishnamurthi ◽  
Mansoor N. Saleh ◽  
Barbara J. Gitlitz ◽  
Mitesh J. Borad ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Abl Tyrosine Kinase ◽  
Abl Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document